Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To determine the appropriate dosing regimen of fosaprepitant for the prevention of CINV in pediatric patients birth to 17 years of age, by assessing the pharmacokinetic and pharmacodynamic parameters, and the safety and tolerability of the administered dose of fosaprepitant, concomitantly with IV ondansetron, in patients from birth to 17 years of age receiving emetogenic chemotherapy (very highly emetogenic chemotherapy [VHEC], highly emetogenic chemotherapy [HEC], or moderately emetogenic chemotherapy [MEC]), or a chemotherapy regimen not previously tolerated due to vomiting, for a documented malignancy.
Critère d'inclusion
- Chemotherapy-induced nausea and vomiting (CINV) associated with emetogenic chemotherapy